Novartis’ Covid treatment shows positive trial results

The treatment, called "ensovibep", is based on DARPin technology, which uses genetically engineered proteins specially designed to neutralize the virus.

RIO DE JANEIRO, BRAZIL - Swiss pharmaceutical giant Novartis announced today, January 10, positive results in Phase 2 trials of a new antiviral treatment against COVID-19 "capable of neutralizing all variants" of the coronavirus, including omicron.

The treatment, called "ensovibep", is based on DARPin technology, which uses genetically engineered proteins specially designed to neutralize the virus.

The trials were carried out in patients with acute cases of Subscribe to our Premium Membership Plan. Already Subscribed?